Sanjeeve Balasubramaniam

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 172 citations · Full text

Cancer Immunosurveillance, Medicine, Recist Progression +10

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang et al. · The Oncologist · 2020 · 171 citations · Full text

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 158 citations

Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction

Douglas C. Palmer, Sanjeeve Balasubramaniam, Ken‐ichi Hanada et al. · The Journal of Immunology · 2004 · 111 citations · Full text

T-regulatory Cell, Immunology, Immunoediting +17

FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis

Shaily Arora, Sanjeeve Balasubramaniam, Wei Zhang et al. · Clinical Cancer Research · 2020 · 99 citations · Full text